Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension

Ítems similars

• Riociguat prevents fibrotic tissue remodelling and improves survival in salt-sensitive Dahl rats
  per: Geschka, Sandra, et al.
  Publicat: (2011)
• No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
  per: Frey, Reiner, et al.
  Publicat: (2011)
• Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality
  per: Becker, Corina, et al.
  Publicat: (2016)
• Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study
  per: Frey, Reiner, et al.
  Publicat: (2016)
• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2009)